Skip to main content

Table 4 Toxicity

From: Bendamustine in patients with relapsed or refractory multiple myeloma

    Subgroups therapy mode Subgroups dosage
Toxicity   All Monotherapy + Steroids p 80-100 mg/m 2 100-120 mg/m 2 p
   n = 39 n = 12 n = 27   n = 21 n = 18  
Anaemia ° I-II 32 (82%) 10 (84%) 22 (81%) 1,0 17 (81%) 15 (83%) 1,0
  ° III-IV 4 (10%) 1 (8%) 3 (11%) 1,0 3 (14%) 1 (6%) 0,6
  ° I-IV 36 (92%) 11 (92%) 25 (92%) 1,0 20 (95%) 16 (89%) 0,6
Neutropenia ° I-II 19 (49%) 5 (42%) 14 (52%) 0,7 8 (38%) 11 (61%) 0,2
  ° III-IV 16 (41%) 6 (50%) 10 (37%) 0,5 11 (52%) 5 (28%) 0,2
  ° I-IV 35 (90%) 11 (92%) 24 (89%) 1,0 19 (90%) 16 (89%) 1
Thrombopenia ° I-II 18 (46%) 4 (33%) 14 (52%) 0,3 9 (43%) 9 (50%) 0,7
  ° III-IV 10 (26%) 4 (33%) 6 (22%) 0,7 8 (38%) 2 (11%) 0,7
  ° I-IV 28 (72%) 8 (66%) 20 (74%) 0,7 17 (81%) 11 (61%) 0,3
Infection ° I-II 3 (8%) 0 (0%) 3 (11%) 0,5 2 (10%) 1 (6%) 1,0
  ° III-IV 6 (15%) 0 (0%) 6 (22%) 0,2 3 (14%) 3 (11%) 1,0
  ° I-IV 9 (23%) 0 (0%) 9 (33%) 0,04 5 (24%) 4 (17%) 1,0
Other Side Effects ° I-II 12 (31%) 3 (25%) 9 (33%) 0,7 10 (48%) 2 (11%) 0,02
  ° III-IV 1 (3%) 0 (0%) 1 (4%) 1,0 0 (0%) 1 (6%) 0,5
  ° I-IV 13 (33%) 3 (25%) 10 (37%) 0,7 10 (48%) 3 (17%) 0,05